A Disappointment in Triple-Negative Breast Cancer A Disappointment in Triple-Negative Breast Cancer

The oral AKT inhibitor ipatasertib does not seem to offer any clinical benefit when added to paclitaxel for women with gene-altered advanced triple- negative breast cancer, indicate phase 3 trial data.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news